Even so, I see meaningful potential. HIMS is expanding into new areas like low testosterone treatment, which could open steady revenue streams if executed well. The key will be management’s ability to tighten compliance, adjust messaging, and rebuild investor confidence. Healthcare is a tough, highly regulated sector, but those that adapt often emerge stronger.
In the short term I remain cautious, but I view this as a healthy test for the company’s resilience. If HIMS can show progress on compliance while scaling its new offerings, I believe the stock has room to rebound and reward patient investors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- blinkix·09-18TOPGreat insights! Love your perspective on HIMS! [Heart]1Report